A 2016 meta-analysis of 43 studies involving 27,905 people in more than 26 countries conflates many of these findings into pooled odds ratios linking suboptimal adherence to virologic failure
. (23) While 15 studies took place in North America, 14 occurred in sub-Saharan Africa, 6 in Europe or Australia, 5 in Asia, and 3 in several countries.
rates were estimated for patients within categorized levels of adherence and logistic regression was used to estimate the overall relationship between virologic failure
and varying levels of adherence.
Comparison of Three Different FDA-Approved Plasma HIV-1 RNA Assay Platforms Confirms the Virologic Failure
Endpoint of 200 Copies per Milliliter Despite Improved Assay Sensitivity.
The researchers counted how many people had a virologic failure
in 1997-1998, 1999-2000, 2001-2002, 20032004, 2005-2006, 2007-2008, and 2009-2011.
Characterization of virologic failure
patients on darunavir/ritonavir in treatment-experienced patients.
was more common among patients who had HCV genotype-la infection than among those who had HCV genotype-1b infection.
Occasionally, transient low-level viremia (ie, a viral blip) is detected by viral load assays, often causing anxiety on the part of patients and clinicians about pending virologic failure
or the emergence of drug resistance The occurrence of viral blips may lead clinicians to order costly and unnecessary tests and alter medication regimens of otherwise well-controlled patients.
When they excluded participants who discontinued the study for reasons other than virologic failure
, the response rates were similar in women and men (73.0 percent vs.
In a study with patients receiving treatment at Costa Rica's Social Security System (Caja Costarricense de Seguro Social, CCSS) where more than 90% of Costa Rica's HIV patients needing treatment receive it, it was determined that virologic failure
(VF) in ART was due to HIV-resistant mutants, and the appearance of these mutants was related to lack of adherence to ART or high viral load at the initiation of treatment (12).
Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure
of protease inhibitor therapy in human immunodeficiency virus-infected adults.
This compared with only one of the five patients in the lopinavir/ritonavir group who experienced virologic failure
Those in the nevirapine group who began nervirapine-based antiretroviral treatment within six months of childbirth were at substantial risk of virologic failure
(41.7% of the 60 women) compared to those in the placebo group (0 cases).